---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-115052"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:26:32.394393+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ironwood Q3 revenue down 19% YoY to $91.6M; LINZESS Rx demand +13%

## Summary
- GAAP net income $3.6M ($0.02 diluted EPS) vs $15.3M ($0.10) a year ago.
- Total revenue $91.6M, down from $113.7M in Q3 2023; cites pricing headwinds.
- LINZESS new-to-brand and extended-unit prescriptions each grew 13% YoY.
- Apraglutide NDA submission for short bowel syndrome on track for Q1 2025.
- Full-year 2024 financial guidance reaffirmed; Adjusted EBITDA $26.2M vs $49.1M.

## SEC filing metadata
- accession: 0001104659-24-115052
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465924115052/0001104659-24-115052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465924115052/tm2427582d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-115052
- JSON: https://secwatch.observer/filing/0001104659-24-115052.json
- Plain text: https://secwatch.observer/filing/0001104659-24-115052.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.